You know if they have downsized from a top number of EE's from 250 to 77 just one month ago - I believe you have your answer. It is not rocket science, the only reason PGNX exists is for a potential takeover which will not happen either since they have no pipeline and no assets
Now the question remains what is considered material information, which the PR of Progenics had promised to release if any before the conference call. Is the requirement of new trial material information? I certainly think so. If FDA does ask for new trial, it would be very hard for the two companies to keep a lid on it, which would be very unfair to low information investors like us. It is also unethical and potentially violating the rules of the security exchange.
On the flip side, if FDA does not require new trial, it would be considered material information as well. They should release it as soon as they know it. Unless, of course, they are still uncertain what to do and waiting for the FDA meeting minutes, which would a very sad conference call.